ZVRA

Zevra Therapeutics Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth↑ 9/10
  • Value↑ 5/10
Zevra Therapeutics sales and earnings growth
ZVRA Growth
Great
  • Revenue Y/Y↑ 177.71%
  • EPS Y/Y↑ 206.77%
  • FCF Y/Y↑ 191.26%
Zevra Therapeutics gross and profit margin trends
ZVRA Profitability
Great
  • Gross margin ↑ 86.10%
  • EPS margin↑ 101.60%
  • ROIC 5Y↑ -39.25%
Zevra Therapeutics net debt vs free cash flow
ZVRA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 18.3

Zevra Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks